Latest Breaking News On - Sarepta therapeutics inc - Page 6 : comparemela.com

Insider Selling: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Insider Sells $508,900.00 in Stock

Insider Selling: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Insider Sells $508,900.00 in Stock
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Royal bankSarepta therapeutics incMather groupPartners investment advisoryRiggs asset managment coPrincipal securities incMontaga associates incSecurities exchange commissionSarepta therapeuticsGet free reportDallan murrayExchange commissionTherapeutics stock downAsset managmentCary street partners investment advisoryStreet partners investment advisory

Pfizer Pauses Gene Therapy Trial For Muscle Disease After Death

Pfizer Pauses Gene Therapy Trial For Muscle Disease After Death
ndtv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ndtv.com Daily Mail and Mail on Sunday newspapers.

Pfizer incSarepta therapeutics incSarepta therapeuticsParent project muscular

Pfizer Pauses Gene Therapy Trial for Muscle Disease After Death

Pfizer Pauses Gene Therapy Trial for Muscle Disease After Death
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.

Sarepta therapeutics incBloomberg pfizer incSarepta therapeuticsParent project muscular

Pfizer pauses trial for experimental gene therapy drug after child participant dies suddenly

Pfizer pauses trial for experimental gene therapy drug after child participant dies suddenly
dailymail.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailymail.co.uk Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesSarepta therapeutics incSarepta therapeutics

Sarepta Therapeutics' (SRPT) "Neutral" Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a research report report published on Thursday morning, Benzinga reports. They currently have a $128.00 target price on the biotechnology company’s stock. Other equities analysts also recently issued research reports about the company. Wedbush reissued an outperform rating and […]

Ian michael estepanMather groupSarepta therapeutics incPartners investment advisoryRiggs asset managment coCantor fitzgeraldPrincipal securities incMontaga associates incSecurities exchange commissionSarepta therapeuticsFree reportModerate buyGet free reportDirector kathryn jean boorExchange commissionMichael estepan